1. |
Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology, 2017, 88(3): 296-303.
|
2. |
Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 2019, 18(5): 459-480.
|
3. |
Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia, 2018, 59(12): 2179-2193.
|
4. |
Ng Y, Collins S D. Clobazam. Neurotherapeutics, 2007, 4(1): 138-144.
|
5. |
Humayun MJ, Samanta D, Carson RP. Clobazam. //StatPearls. Treasure Island (FL): StatPearls Publishing, 2021.
|
6. |
FDA approves onfi for seizures associated with lennox-gastaut syndrome[EB/OL]. Drugs. com, [2022-01-02]. https://www.drugs.com/newdrugs/fda-approves-onfi-seizures-associated-lennox-gastaut-syndrome-2921.html.
|
7. |
唐芯, 向上, 肖农. 氯巴占辅助治疗Lennox-Gastaut综合征的研究进展. 中华神经科杂志, 2015, 47, (12): 1110-1112.
|
8. |
Sankar R. GABAA receptor physiology and its relationship to the mechanism of action of the 1, 5-benzodiazepine clobazam. CNS Drugs, 2012, 26(3): 229-244.
|
9. |
Hashi S, Yano I, Shibata M, et al. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy. European Journal of Clinical Pharmacology, 2015, 71(1): 51-58.
|
10. |
Saruwatari J, Ogusu N, Shimomasuda M, et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and n-desmethylclobazam in japanese patients with epilepsy. Therapeutic Drug Monitoring, 2014, 36(3): 302-309.
|
11. |
Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia, 2009, 50(5): 1158-1166.
|
12. |
Ng Y T, Conry J A, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology, 2011, 77(15): 1473-1481.
|
13. |
Conry JA, Ng Y, Kernitsky L, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop seizure and total seizure improvements over 3 years. Epilepsia, 2014, 55(4): 558-567.
|
14. |
Gidal BE, Wechsler RT, Sankar R, et al. Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study. Neurology, 2016, 87(17): 1806-1812.
|
15. |
Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurologica Scandinavica, 2013, 128(2): 91-99.
|
16. |
Gunning B, Mazurkiewicz-Bełdzińska M, Chin RFM, et al. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials. Acta Neurologica Scandinavica, 2021, 143(2): 154-163.
|
17. |
Lamb A, Dawoud D, Dent R, et al. Cannabidiol with clobazam for seizures associated with Dravet and Lennox-Gastaut syndromes. The Lancet Neurology, 2020, 19(4): 290-291.
|
18. |
Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: the canadian experience. Epilepsia, 1991, 32(1): 11.
|
19. |
Jamil A, Levinson N, Gelfand M, et al. Efficacy and tolerability of clobazam in adults with drug-refractory epilepsy. Neurology, 2021, 11(5): e669-e676.
|
20. |
Kalra V, Seth R, Mishra D, et al. Clobazam in refractory childhood epilepsy. The Indian Journal of Pediatrics, 2010, 77(3): 263-266.
|
21. |
Bresnahan R, Martin-McGill KJ, Williamson J, et al. Clobazam add-on therapy for drug-resistant epilepsy. Cochrane Database of Systematic Reviews, 2019, 10(10): CD004154.
|
22. |
Montenegro MA, Cendes F, Noronha ALA, et al. Efficacy of Clobazam as Add-On Therapy in Patients with Refractory Partial Epilepsy. Epilepsia, 2001, 42(4): 539-542.
|
23. |
Buchanan N. Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. Journal of the Royal Society of Medicine, 1993, 86(7): 378-380.
|
24. |
Koeppen D, Baruzzi A, Capozza M, et al. Clobazam in therapy-resistant patients with partial epilepsy: a double-blind placebo-controlled crossover study. Epilepsia, 1987, 28(5): 495-506.
|
25. |
Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Canadian Journal of Neurological Sciences, 1990, 17(3): 317-319.
|
26. |
Sivakumar S, Ibrahim M, Parker D, et al. Clobazam: an effective add-on therapy in refractory status epilepticus. Epilepsia, 2015, 56(6): e83-e89.
|
27. |
Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia, 1998, 39(9): 952-959.
|
28. |
Arya R, Giridharan N, Anand V, et al. Clobazam monotherapy for focal or generalized seizures. Cochrane epilepsy group. Cochrane Database of Systematic Reviews, 2018, 2018(7).
|
29. |
Dulac O, Figueroa D, Rey E, et al. Monotherapy with clobazam in epilepsies in children. Presse Medicale, 1983, 12(17): 1067-1069.
|
30. |
Mehndiratta MM, Krishnamurthy M, Rajesh KN, et al. Clobazam monotherapy in drug naive adult patients with epilepsy. Seizure, 2003, 12(4): 226-228.
|
31. |
Clobazam adjunctive treatment of adults with refractory focal epilepsy[EB/OL]. [2022-01-02]. https://clinicaltrials.gov/ct2/show/record/NCT02726919.
|
32. |
Clobazam use in epilepsia partialis continua—pilot study[EB/OL]. [2022-01-02] .https://clinicaltrials.gov/ct2/show/NCT02134366.
|
33. |
Clobazam Tablets—FDA prescribing information, side effects and uses[EB/OL]. Drugs.com, [2022-01-02]. https://www.drugs.com/pro/clobazam-tablets.html.
|
34. |
Thomas SV, Jose M, Divakaran S, et al. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India. Epilepsia, 2017, 58(2): 274-281.
|
35. |
FDA Drug Safety Communication: FDA warns of serious skin reactions with the anti-seizure drug Onfi (clobazam) and has approved label changes[EB/OL]. FDA(2019-06-21)[2022-01-02]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-serious-skin-reactions-anti-seizure-drug-onfi-clobazam-and.
|
36. |
Gauthier AC, Mattson RH. Clobazam: a safe, efficacious, and newly rediscovered therapeutic for epilepsy. CNS Neuroscience & Therapeutics, 2015, 21(7): 543-548.
|